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Abstract
Background Primary hyperparathyroidism (pHPT) in pregnancy is reported to be associated with significant
maternal and foetal complications and an up to threefold increase in the risk of miscarriage. However, the true
incidence of pHPT in pregnancy, complete and miscarried, is unknown and there are no data on the prevalence of
undiagnosed pHPT in recurrent miscarriage (RM) (C3 consecutive miscarriages under 24-week gestation). This is
the first prospective study aiming to establish the prevalence of undiagnosed pHPT in RM.
Methods Following UK National ethics committee approval, women who had experienced 3 or more consecutive
miscarriages were recruited from a nationwide RM clinic. Serum corrected calcium, phosphate, PTH and vitamin D
were evaluated. Patients with raised serum calcium and/or PTH were recalled for confirmatory tests. Power calcu-
lations suggested that a minimum of 272 patients were required to demonstrate a clinically significant incidence of
pHPT.
Results Three hundred women were recruited, median age 35 years (range 19–42). Eleven patients had incomplete
data, leaving 289 patients suitable for analysis; 50/289 patients (17%) with abnormal tests were recalled. The
prevalence of vitamin D deficiency (\25 nmol/l) and insufficiency (25–75 nmol/l) was 8.7 and 67.8%, respectively.
One patient was diagnosed with pHPT (0.34%) and underwent successful parathyroidectomy.
Conclusions The prevalence of undiagnosed pHPT (0.34%) in RM in this study appears to be many times greater
than the 0.05% expected in this age group. The findings of this pilot study merit follow-up with a larger-scale study.
Routine serum calcium estimation is not currently undertaken in RM and should be considered.
Introduction
Primary hyperparathyroidism (pHPT) is the third com-
monest endocrine disorder after diabetes and thyroid dis-
ease [1–3], with a prevalence of 0.15–0.4% in the general
population and twofold female preponderance [2, 4]. The
majority of patients with pHPT are diagnosed in late
middle age onwards, with less than 1% currently diagnosed
during pregnancy [3–5]. However, serum calcium is not
routinely measured in pregnancy so the true incidence of
pHPT in the gravid woman, complete and miscarried, is
unknown.
Miscarriage is defined as the loss of a foetus at any time
from conception to week 24 of pregnancy and recurrent
miscarriage, according to WHO guidelines, three or more
consecutive miscarriages before week 24 [6]. The largest
surgical case series of pHPT in pregnancy reports a
threefold risk of miscarriage, with the rate of foetal loss
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progressively increasing with maternal serum calcium [5].
However, this study is likely to suffer from sampling bias,
the methodology having been enquiry about a prior history
of miscarriage in patients already diagnosed with pHPT
and selected for parathyroidectomy. Larger retrospective
cohort studies from registry data in Israel [7] and Denmark
[1] do not, at face value, appear to corroborate the findings
of this study.
RM affects 1% of couples trying to conceive and results
in considerable psychological burden. Despite this, it has
historically been a neglected area of research, and as a
result, the causes are not well understood. Our hospital runs
the UK’s largest specialist tertiary referral clinic for
women with RM, receiving referrals from all over the UK
and beyond. At present, investigations for potential causes
of RM do not include screening for pHPT with serum
calcium estimation, despite the fact that it is possible that
this is contributory and reversible with parathyroidectomy.
There has been no previous prospective data on the
prevalence of undiagnosed pHPT in women experiencing
consecutive recurrent miscarriage (RM). This prospective
pilot study was therefore devised to establish the preva-
lence of undiagnosed pHPT in RM patients and assess
whether routine screening for pHPT in this population may
be justified.
Materials and methods
Following national ethics committee approval, recruitment
was undertaken in our hospital’s RM clinic, of women who
had experienced 3 or more consecutive miscarriages at
under 24 weeks. Exclusion criteria were failure to meet the
definition of RM, previous parathyroid or thyroid surgery, a
known MEN syndrome, lithium use and current pregnancy.
Figure 1 shows patient flow through the study. Serum
corrected calcium, phosphate, PTH and vitamin D were
evaluated. Elevated serum calcium was defined as an
albumin-corrected value[2.6 mmol and PTH[6.8 pmol/l.
Vitamin D deficiency was defined as a 25-hydroxyvitamin
D of\25 nmol/l, insufficiency as 25–75 nmol/l and ade-
quacy C75 nmol/l.
Patients with vitamin D deficiency or insufficiency in
isolation were treated with vitamin D supplements, and
serum calcium, PTH and vitamin D were rechecked fol-
lowing treatment to confirm normalization of the bio-
chemistry. Ongoing care was then transferred back to the
RM clinic and general practitioner. Patients with a raised
serum calcium and/or PTH had their tests repeated and
were recalled for review by a consultant endocrine surgeon
(FP). At recall, those with results excluding pHPT were
discharged to their general practitioner and RM clinic.
Patients with results potentially still compatible with pHPT
and with coexistent vitamin D deficiency or insufficiency
were treated with cholecalciferol 20,000 units twice weekly
for 6 weeks and their biochemical profile repeated. Per-
sistently abnormal results prompted further investigation
for possible primary hyperparathyroidism and a follow-up
visit.
Parathyroid hormone in the study patients was measured
using automated immunoassays (Abbott Architect and
Immulite 2000, Siemans, Llanberis, UK). 25-Hydroxyvi-
tamin D was measured using the automated liaison assay
(Diasorin, Saluggia, Italy). Coefficient of variation was
\8% and\11%, respectively, across the diagnostic range
[8].
At the time the study was designed, the best available
data suggested a background prevalence of pHPT in
women of reproductive age of 36/100,000 [9]. The required
sample size was calculated using the STATA corporation
statistical platform [10, 11] and based on detecting a
change in prevalence from 0.036% (i.e. 36/100,000) in the
general population to 1% or more in the RM population.
One per cent prevalence for pHPT in the RM group was
chosen as it is generally regarded as the lowest value that
may stimulate a change in clinical practice. A one-tailed
test, with a power of 80% (i.e. b = 0.2) and significance
level (a) of 5%, showed a minimum requirement of 272
RM patients with binomial 95% confidence intervals
around the 1% prevalence of 0.23–3.19%. Descriptive
statistics were calculated in Excel (V14.6, 2010,
Microsoft, Washington, USA).
Results
Three hundred women with a median age of 35 years
(19–42) were recruited from the RM clinic over a 2-year
period. Figure 1 shows their progress through the study.
All patients were eligible for inclusion; none met the
exclusion criteria. Eleven patients who had incomplete
data, mainly due to failure to attend for initial or follow-up
investigations and after attempts to contact them directly
and via their general practitioner, were excluded from the
study leaving 289 women. Table 1 shows their results:
median serum corrected calcium was 2.38 mmol/l (range
2.09–2.71 mmol/l) and PTH 5.2 (range 1.3–18.4). Median
vitamin D level was 53.8 nmol/l (range 6.4–134 nmol/l)
with a prevalence of vitamin D deficiency (25-hydroxyvi-
tamin\25 nmol/l) and insufficiency (25–75 nmol/l) in the
whole cohort of 8.7% and 67.8%, respectively. Only 22.8%
were vitamin D replete (C75 nmol/l).
Fifty patients (17%) were recalled due to results suspi-
cious for pHPT (Fig. 2). In addition, 110 (38%) were found
to have inadequate levels of vitamin D in isolation
(\75 nmol/l). These women were commenced on
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supplements and after normalization of their biochemistry
returned to standard care in the RM clinic. Of the 50
recalled patients, 19 had a diagnosis of pHPT excluded at
their recall appointment and 31 were investigated further:
Fifteen of those required vitamin D supplementation, the
others undergoing repeat biochemical testing of blood and
urine alone. Ultimately, one patient had results that, after
vitamin D supplementation and assessment of the urinary
calcium excretion, confirmed pHPT. This patient, aged 34,
had a history of 3 previous consecutive miscarriages
between 2- and 9-weeks gestation with no successful
pregnancies. Her other past medical history was of




migraine and chest pain, for which she had consulted her
GP and attended the emergency department, with no cause
elucidated. She had had no renal calculi nor fragility
fractures. Her bone density was unknown. There was no
family history of endocrine disease nor features suggestive
of a genetic syndrome. Corrected calcium at presentation
was 2.6 mmol/l, PTH 18.4 pmol/ml, phosphate 0.92 mmol/
l and 25-hydroxyvitamin D 31 nmol/l. Vitamin D supple-
mentation was instituted as described above. This
improved the serum 25-hydroxyvitamin D (to 102 nmol/l),
but the calcium remained elevated at 2.64 mmol/l and PTH
at 13.4 pmol/ml. Urinary calcium concentration was
2.83 mmol/l, totalling 4.95 mmol over 24 h, and calcium/
creatinine clearance ratio was 1.52% [12]. Given her uri-
nary calcium/creatinine clearance ratio, age of 34 and
absence of a family history, she did not fulfil our depart-
mental criteria for genetic testing for either FHH or MEN
and so went on to have localization studies in the form of a
neck ultrasound and SestaMIBI with SPECT. These
showed only a multinodular goitre and no areas of abnor-
mal tracer uptake or retention. Following discussion with
the patient and after obtaining full, informed, written
consent, parathyroidectomy was performed. A bilateral
neck exploration was undertaken under general anaesthesia
via a standard cervicotomy.
At operation, the thyroid gland was nodular but not
significantly enlarged, and four parathyroid glands were
found in eutopic positions, with a single, abnormal left
superior parathyroid adenoma, which was removed.
Recurrent laryngeal nerves were identified and preserved
Fig. 2 Serum PTH (y-axis) vs corrected calcium (x-axis) for every patient. Upper limits of normal are shown in red (serum PTH[ 6.8 pmol/l)
and green (corrected calcium[ 2.6 mmol/l). Single patient with phHPT in yellow circle
Table 1 Demographics and biochemical parameters of the study participants
Variable Median Range pHPT patient (values at initial review and pre-op)
Age at enrolment (years) 35 19–42 34
Corrected calcium (mmol/l) 2.38 2.09–2.71 2.60, 2.64
PTH (pmol/ml) 5.2 1.3–18.4 18.4, 13.4
25-OH-vitamin D (nmol/l) 53.8 6.4–134 31, 102
Normal ranges, corrected calcium 2.20–2.60 mmol/l, PTH 1.1–6.8 pmol/ml, 25-OH-vitamin D 75–150 nmol/l
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with good signal on the neural monitor (NIM, Med-
tronicTM, USA). Intra-operative PTH (STAT IO-I-PTH,
Future Diagnostics Solutions B.V., Wijchen, Netherlands)
fell to less than 50% of the maximal value by 10 min after
excision of the abnormal parathyroid gland [13].
Histopathology confirmed a parathyroid adenoma com-
posed predominantly of oxyphil cells and measuring
18 9 17 9 3 mm, weight 0.44 g. Fibreoptic nasendoscopy
performed pre- and post-operatively showed normal vocal
cord function. At two-week follow-up, the patient was well
with no complications and biochemical cure was confirmed
with a corrected serum calcium of 2.22 mmol/l and PTH of
2.3 pmol/l. At six-month follow-up, the patient’s bio-
chemistry remained normal. She had not yet attempted to
conceive but was planning to start in autumn 2017.
The prevalence of confirmed pHPT in this cohort of
patients with RM was therefore 1 in 289, i.e. 0.34%.
Discussion
The aim of this study was to ascertain the incidence of
pHPT in a population with RM in order to move closer to
understanding whether there is causality. The study was
designed prospectively, the first of its kind, as a pilot,
whose results would inform a future larger trial, if justified.
One significant difficulty in establishing whether the inci-
dence of 0.34% in RM is of clinical relevance is the lack of
a high-quality control group of non-pregnant women of
childbearing age, or of pregnant women not experiencing
RM. Until recently, the majority of the published literature
on pHPT in women of childbearing age focused on indi-
vidual cases of pHPT in pregnant women with case reports
and small series, covering 119 patients between 1998 and
2017 and reporting mostly on the complications of pHPT in
pregnancy including foetal loss in 37 cases [14–29].
One case series of women undergoing parathyroidec-
tomy over a 6 year period at a single centre in Florida
reported a prevalence of pHPT in women of reproductive
age (16–44 years) of 8% (360 of 4500 women). This
improbably high prevalence is likely to reflect referral bias
to this high-volume specialist centre. Data derived from
hospital admissions in Switzerland showed an in-hospital
prevalence of pHPT totalling 36.3 per 100,000 women
(0.04%) aged 15 to 39 years [9]. Potentially the largest
study of all, a Danish registry study of women aged
16–44 years reported 1057 cases of pHPT (based on ICD8
and ICD10 codes) amongst all patients registered in the
‘National Hospital Discharge Register, LPR’ in the
33 years from January 1977 to December 2010, but did not
state a denominator, preventing calculation of the preva-
lence [1]. The largest and probably most reliable study to
report a prevalence was based on serum biochemistry,
rather than hospital coding, derived from data held by a
large Israeli healthcare organization: the serum calcium
and PTH testing performed on 292,024 Israeli women aged
20–40 retrospectively identified 159 women, equating to
0.05% with pHPT.
The risk of foetal loss in pregnant women with pHPT is,
according to the retrospective surgical series of 32 pregnant
women undergoing parathyroidectomy, elevated threefold
[5]. This study also showed a correlation between
increasing maternal serum calcium and the rate of foetal
loss with the percentage of pregnancies ending in miscar-
riage rising progressively from 12.5% at a serum calcium
of 2.59–2.67 mmol/l to 80% at 3.04–3.24 mmol/l. This
would seem to strengthen the argument that there is a
causative association between the biochemical severity of
pHPT and miscarriage. Indeed, although the Israeli study
[7] did not show a significant difference in miscarriage
between their pHPT (n = 74) and control groups, it was
characterized by a very mild median hypercalcaemia of
2.67 mmol/l (range 2.59–3.17 mmol/l) corresponding to
the mildest subgroup within the 32 patient surgical series
[5]. The single hyperparathyroid patient in our study also
had a mild hypercalcaemia at 2.64 mmol/l. The Danish
registry study [1] showed a non-significant increase in the
risk of abortion in the year after diagnosis with pHPT
(relative risk = 1.5, 95% confidence interval 0.81–2.74) and
those women who underwent surgery for their pHPT had a
higher rate of stillbirth before the time of diagnosis of
pHPT compared to those with pHPT who did not undergo
surgery. This may also reflect a relationship between dis-
ease severity and risk of pregnancy loss; however, serum
calcium was not reported in this study.
The existing data therefore appear to be statistically
insufficient to exclude a genuine nexus between pHPT in
patients with RM and are further complicated by the dif-
ficulty in retrospective studies in establishing the time of
onset of pHPT in relation to pregnancy and miscarriage. To
this, one should add the possible underestimation in the
incidence of pHPT in women who do become pregnant due
to the overlap in non-specific symptoms associated with
pHPT and pregnancy and the diagnostic challenge caused
by the physiological changes of pregnancy that may mask
the biochemical features of pHPT.
It should be emphasized that the population in our study
group refers specifically to women who have experienced
three or more consecutive miscarriages in whom no other
aetiology has been identified. This represents approxi-
mately 1% of all couples trying to conceive [30]. The
likelihood of this event occurring along with pHPT in a
single woman of reproductive age, using the Israeli cohort
of 0.05% [1], without causality and completely by chance
could therefore be estimated at 0.0005%, nearly 700-fold
less than the result of our study.
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On a side note, the prevalence of vitamin D deficiency
and insufficiency of 8.7 and 67.8% respectively in this
study is in keeping with previous studies which range from
5–50% depending upon the definition and the ethnic mix of
the population, with lower levels being more prevalent in
black and Asian women [31, 32]. Vitamin D deficiency
may result in maternal osteomalacia, myopathy and cran-
iotabes as well as neonatal rickets and possibly intrauterine
growth retardation [33, 34], but importantly it is not an
independent risk factor for miscarriage. One reason for
measuring and correcting vitamin D in this study group
was to ensure that cases of normocalcaemic hyper-
parathyroidism, masked by vitamin D insufficiency, were
not missed.
The optimal management of pHPT in women with RM in
the non-pregnant state is parathyroid surgery, in accordance
with NIH guidelines [35]. When pHPT is diagnosed in
pregnancy, the treatment requires an assessment of the risks
to mother and foetus of parathyroid surgery against the risks
to both of postponing surgical treatment and issues of
localization studies, i.e. the risk of radiation exposure to the
foetus if SestaMIBI scanning is used must be considered
In conclusion, this is the first prospective study of pHPT
in RM patients. The prevalence of undiagnosed pHPT of
0.34% in RM appears to be many times higher than
expected in this age group according to the published lit-
erature. This pilot study justifies further study of the
potentially important relationship between pHPT and RM
with a larger sample size. At present in the UK, women
experiencing RM do not undergo routine serum calcium
estimation. Given the distress caused by RM versus the low
cost of screening and the potential benefits of identifying a
potentially reversible cause with a curative parathyroidec-
tomy, it appears that routine serum calcium and PTH
estimation is justified in the RM population.
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